SlideShare a Scribd company logo
1 of 30
ACUTE TOXICOLOGY
OECD GUIDELINES
425
Presented by
PURANAM SOUMYA
Y18PHD0417
III-PHARM.D
TOXICOLOGY
 Toxicology is the scientific study of adverse
effects that occur in living organisms due to
chemicals.
 It involves observing and reporting
symptoms, mechanisms, detection and
treatments of toxic substances, in particular
relation to the poisoning of humans.
 Toxicity tests are mostly used to examine
specific adverse events such as cancer,
cardiotoxicity and skin/eye irritation
ANIMAL TOXICITY TEST
Acute toxicity
Sub-acute (repeated doses) toxicity
Sub-chronic toxicity
Chronic toxicity
Special toxicity
14 days
28 days
3 months
6 months to 2 yrs.
e.g. Carcinogenicity
ACUTE ORAL TOXICITY
 Acute toxicity testing is carried out to determine the effect of a single dose on a particular
animal species.
 In acute toxicological testing, the investigational product is administered at different
dose levels, and the effect is observed for 14 days.
 All mortalities caused by the investigational product during the experimental period are recorded
and morphological, biochemical, pathological, and histological changes in the dead animals are
investigated.
 Acute toxicity testing permits the 50% lethal dose (LD50) of the investigational product to be
determined.
 Acute toxicity studies provide information on:
• The potential for acute toxicity in humans;
• An estimate of safe acute doses for humans;
• The potential target organs of toxicity;
• Time course of drug-induced clinical observations;
• The appropriate dosage for multiple-dose toxicity studies; and
• Species differences in toxicity.
OECD GUIDELINES FOR ACUTE ORAL TOXICITY
Number TITLE Date of Adoption
420 Fixed dose procedure 17 December 2001
425 Up and down procedure 3 October 2008
425 : Acute oral toxicity – Up and Down Procedure
(UDP)
INTRODUCTION
• The concept of the up-and-down testing approach was first described by Dixon and Mood.
• In 1985, Bruce proposed to use an up-and-down procedure (UDP) for the determination of acute
toxicity of chemicals .
• A study comparing the results obtained with the UDP, the conventional LD50 test and the Fixed
Dose Procedure (FDP,OECDTest Guideline 420) was published in 1995.
• The test procedure described in this Guideline is of value in minimizing the number of animals
required to estimate the acute oral toxicity of a chemical. In addition to the estimation of LD50
and confidence intervals, the test allows the observation of signs of toxicity.
• The testing laboratory should consider all available information on the test substance prior to
conducting the study.
• It will include
-Identity and chemical structure of the test substance;
-Physical chemical properties;
-Results of any other in vitro or in vivo toxicity tests on the substance;
-Toxicological data on structurally related substances or similar mixtures;
-Anticipated use(s) of the substance.
• This information is useful to determine the relevance of the test for the protection of human
health and the environment, and will help in the selection of an appropriate starting dose.
• The method permits estimation of an LD50 with a confidence interval and the results allow a
substance to be ranked and classified according to the Globally Harmonised System for the
classification of chemicals which cause acute toxicity.
INITIAL CONSIDERATIONS
• Dose starting near 175mg/kg and using half log units (dose progression by
factor 3.2) between doses will procedure best results.
• Test substances, at doses that are known to cause marked pain and distress
due to corrosive or severely irritant actions, need not be administered.
• Moribund animals or animals obviously in pain or showing signs of severe and
enduring distress shall be humanely killed, and are considered in the
interpretation of the test results in the same way as animals that died on test.
• The method would not be practical to use when considerably delayed death
(five days or more) can be expected.
PRINCIPLE OF LIMIT TEST
• The LimitTest is a sequential test that uses a maximum of 5 animals.A test dose of 2000, or
exceptionally 5000 mg/kg, may be used.
• The selection of a sequential test plan increases the statistical power and also has been made
to intentionally bias the procedure towards rejection of the limit test for compounds with
LD50s near the limit dose.
PRINCIPLE OF MAIN TEST
• The main test consists of a single ordered dose progression in which animals are dosed, one at a
time, at a minimum of 48-hour intervals.
• The first animal receives a dose a step below the level of the best estimate of the LD50.
• If the animal survives, the dose for the next animal is increased by [a factor of]
• 3.2 times the original dose; if it dies, the dose for the next animal is decreased
• by a similar dose progression.
• Each animal should be observed carefully for up to 48 hours before making a
decision on whether and how much to dose the next animal.
• That decision is based on the 48-hour survival pattern of all the animals up to
• that time.
• The LD50 is calculated using the method of maximum likelihood
DESCRIPTION OF METHOD
Selection of animal species
• The preferred rodent species is the rat ,normally female rats are used.
• When toxicological or toxicokinetic properties of structurally related chemicals
are studied, males are likely to be more sensitive.
• Criteria for female rats
-They should be nulliparous and non pregnant. -
-Should be between 8 to 12 years old.
-Weight ± 20% of initial mean weight
Housing and feeding
• Temperature - 22°C (± 3°C).
• Humidity – 50 – 60% not exceeding 70%
• Lighting should be artificial, the sequence being 12 hours light and 12
hours dark.
• The animals are housed individually.
• For feeding, conventional rodent laboratory diets may be used with an
unlimited supply of drinking water.
Preparation of animals
• The animals are randomly selected, marked to permit individual identification, and
kept in their cages for at least 5 days prior to dosing to allow for acclimatization to
laboratory conditions.
• Ensure that animals are available in the appropriate size and age range for
the entire study.
Preparation of doses
• Test substances should be administered in a constant volume by varying the
concentration of the dosing preparation.
• In rodents, the volume should not normally exceed 1 ml/100g of body weight; however
in the case of aqueous solutions, 2 ml/100g body weight can be considered.
• For vehicles other than water, the toxicological characteristics of the vehicle should
be known.
PROCEDURE
Administration of Doses
• The test substance is administered in a single dose by gavage using a
stomach tube or a suitable intubation cannula.
• Animals should be fasted prior to dosing (e.g., with the rat, food but not
water should be withheld overnight; with the mouse, food but not water
should be withheld for 3-4 hours).
• The animals should be weighed and the test substance administered and
the dose is calculated according to the body weight.
• After the substance has been administered, food may be withheld for a
further 3-4 hours in rats or 1-2 hours in mice.
Limit test and Main Test
• The limit test is primarily used in situations where the experimenter has
information indicating that the test material is likely to be nontoxic, i.e.,
having toxicity below regulatory limit doses.
• There is little or no information about its toxicity, or in which the test
material is expected to be toxic, the main test should be performed.
• Information about the toxicity of the test material can be gained from
knowledge about similar tested compounds or similar tested mixtures or
products, taking into consideration the identity and percentage of
components.
Limit Test
Limit Test at 2000 mg/kg
• Dose one animal at the test dose.
• If the animal dies, conduct the main test to determine the LD50.
• If the animal survives, dose four additional animals sequentially so that a total of
five animals are tested. If three animals die, the limit test is terminated and the
main test is performed.
• If an animal unexpectedly dies late in the study, and there are other survivors, it is
appropriate to stop dosing and observe all animals to see if other animals will also
die during a similar observation period.
• The results are evaluated as follows (O=survival, X=death).
• The LD50 is less than the test dose (2000 mg/kg) when three or
more animals die.
O XO XX
O OX XX
O XX OX
O XX X
If a third animal dies, conduct the main test.
• Test five animals.The LD50 is greater than the test dose
(2000 mg/kg) when three or more animals survive.
O OO OO
O OO XO
O OO OX
O OO XX
O XOXO
OXOOO/X
O OXXO
OOXOO/X
O XXOO
Limit Test at 5000 mg/kg
• Dose one animal at the test dose.
• If the animal dies, conduct the main test to determine the LD50.
• If the animal survives, dose two additional animals. If both animals survive, the
LD50 is greater than the limit dose and the test is terminated.
• The LD50 is less than the test dose (5000 mg/kg) when three or more animals die.
O XO XX
O OX XX
O XX OX
OXXX0.
The LD50 is greater than the test dose (5000 mg/kg) when three or more animals
survive.
OOO
O XOXO
O XOO
O OXXO
O OXO
OXXOO
Main Test
• Single animals are dosed in sequence usually at 48 h intervals.
• For selecting the starting dose, information on structurally related
substances and results of any other toxicity tests on the test material, should
be used to approximate the LD50 as well as the slope of the dose- response
curve.
• The dose progression factor should remain constant throughout testing.
• When there is no information on the slope of the substance to be tested, a
dose progression factor of 3.2 is used.
• Using the default progression factor, doses would be selected from the
sequence 1.75, 5.5, 17.5, 55, 175, 550, 2000 (or 1.75, 5.5, 17.5, 55, 175, 550,
1750, 5000 for specific regulatory needs).
1 animal
1.75mg/kg
If the animal
survives
If the animal dies
Next animal receives the higher dose
5.5mg/kg
Classify GHS
category 1
1 animal
5.5mg/kg
If the animal survives If the animal dies
Next animal receives the higher dose
17.5mg/kg
Animal receives lower
dose
 The testing stops when one of the following stopping criteria first is met:
(a)3 consecutive animals survive at the upper bound;
(b)5 reversals occur in any 6 consecutive animals tested;
(c)at least 4 animals have followed the first reversal and the specified
likelihood-ratios exceed the critical value.
• If an animal unexpectedly dies late in the study and there are other survivors
at that dose or above, it is appropriate to stop dosing and observe all animals
to see if other animals will also die during a similar observation period.
• If subsequent survivors also die, and it appears that all dose levels exceed the
LD50 it would be most appropriate to start the study again.
• If subsequent animals survive at or above the dose of the animal that dies, it
is not
necessary to change the dose progression.
OBSERVATIONS
• Animals are observed individually at least once during the first 30 minutes after dosing, periodically
during the first 24 hours for 14 days.
• The times at which signs of toxicity appear and disappear are recorded.
• Observations should include
- changes in skin and fur
- eyes and mucous membranes
- respiratory, circulatory
- autonomic and central nervous systems
- somatomotor activity
- behaviour pattern
- tremors, convulsions
- salivation
- diarrhoea
- lethargy
- sleep and coma.
• Animals found in a moribund condition and animals showing severe pain or enduring signs of severe
distress should be humanely killed and time of death should be recorded.
Bodyweight
• Individual weights are recorded before the test drug administration and
weekly thereafter.
• At the end of the test surviving animals are weighed and then humanely
killed.
Pathology
• All animals (including those which die during the test or are removed
from the
study for animal welfare reasons) should be subjected to gross necropsy.
• Microscopic examination of organs showing evidence of gross
pathology in animals surviving 24 or more hours after the initial
dosing may also be considered.
DATA AND REPORTING
All data should be summarized in tabular form, showing for each test dose,
-number of animals used
-number of animals displaying signs of toxicity
-number of animals found dead during the test or killed for humane reasons
-time of death of individual animals
-a description and the time course of toxic effects and reversibility
-necropsy findings.
CALCULATION OF LD 50
The LD50 is calculated using the maximum likelihood method Likelihood
function is written as follows:
L = L1 L2 ....Ln ,
where L is the likelihood of the experimental outcome, µ and σ, and n the total number of
animals tested.
Li = 1 - F(Zi) ,if the ith animal survived,
or Li = F(Zi) if the ith animal died,
where F = cumulative standard normal distribution,
Zi = [log(di) - µ ] / σ
di = dose given to the ith animal
σ = standard deviation in log units of dose (usually 0.5)
Estimated LD50 are available for these circumstances given below:
a) If the upper bound dose ended testing, then the LD50 is reported to be above the upper
bound.
b) If all the dead animals have higher doses than all the live animals, then the LD50 is
between the doses for the live and the dead animals which do not give exact value of
LD50.
c) If the live and dead animals have only one dose in common and all the other dead
animals
have higher doses and all the other live animals lower doses, or vice versa, then the LD50
equals their common dose.
 Maximum likelihood calculation can be performed using either SAS (e.g., PROC NLIN) or
BMDP (e.g., program AR) computer program packages.
Computation of Confidence Interval
Confidence intervals provides valuable information on the reliability and utility of
the main test that was conducted
• A wide confidence interval indicates that there is more uncertainty
associated with the estimated LD50. The reliability of the estimated LD50 is
low and the usefulness of the estimated LD50 may be marginal.
• A narrow interval indicates that there is relatively little uncertainty associated
with the estimated LD50. The reliability of the estimated LD50 is high and the
usefulness of the estimated LD50 is good.
• This means that if the main test were to be repeated, the new estimated LD50
should be close to the original estimated LD50 and both of these estimates
should be close to the true LD50.
TEST REPORT
The test report must include the following information:
• Test substance:
–physical nature, purity and, where relevant, physical-chemical properties
(including isomerization);
–identification data, including CAS number.
• Vehicle (if appropriate):
–justification for choice of vehicle, if other than water.
• Test animals:
–species/strain used;
–microbiological status of the animals, when known;
–number, age and sex of animals (including, where appropriate, a rationale for use
of males instead of females);
–source, housing conditions, diet, etc.
• Test conditions:
– rationale for initial dose level selection, dose progression factor and for follow-up dose
levels;
– details of test substance formulation including details of the physical form of the material
administered;
– details of the administration of the test substance including dosing volumes and time of
dosing;
– details of food and water quality (including diet type/source, water source).
Results:
– body weight/body weight changes;
– tabulation of response data and dose level for each animal (i.e., animals showing signs of
toxicity including nature, severity, duration of effects, and mortality);
– individual weights of animals at the day of dosing, in weekly intervals thereafter, and at
the time of death or sacrifice ;
– time course of onset of signs of toxicity and whether these were reversible for each animal;
– necropsy findings and any histopathological findings for each animal, if available; − LD50
data;
– statistical treatment of results.
Comparison of guidelines
Criteria 420 423 425
Dose 5 to 5000 mg/kg 5 to 5000 mg/kg 1st animal dose less than
estimated LD50
outcome by factor 3.2
Grouping of animal Group of 5 animal of
one sex
Three animals per
group
One animal per group
Estimation of end
point
1 animal expected to
die
2-3 animal
expected to die
2-3 animal expected to
die
Sighting study Present Absent Absent
AT425.pptx

More Related Content

What's hot

Acute eye irritation(1)
Acute eye irritation(1)Acute eye irritation(1)
Acute eye irritation(1)Rajesh Yadav
 
Acute oral toxicity-UDP : oecd-425
Acute oral toxicity-UDP : oecd-425Acute oral toxicity-UDP : oecd-425
Acute oral toxicity-UDP : oecd-425Dr Ajay Mandal
 
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).helasri gummadi
 
Oecd guidelines for toxicology studies
Oecd guidelines for toxicology studiesOecd guidelines for toxicology studies
Oecd guidelines for toxicology studiesJasdeep singh brar
 
chronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECDchronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECDSohil Shah
 
Inhalation Toxicity Studies- OECD guidelines
 Inhalation Toxicity Studies- OECD guidelines Inhalation Toxicity Studies- OECD guidelines
Inhalation Toxicity Studies- OECD guidelinesCerin Philip
 
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407Tulsi Gulabrao Patil
 
OECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicityOECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicityShital Magar
 
Acute eye irritation test as per OECD guidelines
Acute eye irritation test as per OECD guidelinesAcute eye irritation test as per OECD guidelines
Acute eye irritation test as per OECD guidelinesmadhvi Chaubey
 
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptxTOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptxAnmolkanda06
 
Acute dermal irritation/corrosion: OECD 404
Acute dermal irritation/corrosion: OECD 404Acute dermal irritation/corrosion: OECD 404
Acute dermal irritation/corrosion: OECD 404Dr Ajay Mandal
 
Oral toxicity
Oral toxicityOral toxicity
Oral toxicityDiana Lou
 
Toxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal IrritationToxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal IrritationShubhu20
 
Regulatory guidelines for conducting toxicity studies by ich
Regulatory guidelines for conducting toxicity studies by ichRegulatory guidelines for conducting toxicity studies by ich
Regulatory guidelines for conducting toxicity studies by ichAnimatedWorld
 
Safety pharmacology studies
Safety pharmacology studies Safety pharmacology studies
Safety pharmacology studies Santosh Sai
 
Regulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studiesRegulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studiesHimikaRathi
 
Acute toxicity study for inhalation
Acute toxicity study for inhalationAcute toxicity study for inhalation
Acute toxicity study for inhalationDRx Priya Shukla
 

What's hot (20)

Acute eye irritation(1)
Acute eye irritation(1)Acute eye irritation(1)
Acute eye irritation(1)
 
Acute oral toxicity-UDP : oecd-425
Acute oral toxicity-UDP : oecd-425Acute oral toxicity-UDP : oecd-425
Acute oral toxicity-UDP : oecd-425
 
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
 
Oecd guidelines for toxicology studies
Oecd guidelines for toxicology studiesOecd guidelines for toxicology studies
Oecd guidelines for toxicology studies
 
chronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECDchronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECD
 
Inhalation Toxicity Studies- OECD guidelines
 Inhalation Toxicity Studies- OECD guidelines Inhalation Toxicity Studies- OECD guidelines
Inhalation Toxicity Studies- OECD guidelines
 
REPRODUCTIVE TOXICITY STUDIES
REPRODUCTIVE TOXICITY STUDIESREPRODUCTIVE TOXICITY STUDIES
REPRODUCTIVE TOXICITY STUDIES
 
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407
 
OECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicityOECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicity
 
Acute eye irritation test as per OECD guidelines
Acute eye irritation test as per OECD guidelinesAcute eye irritation test as per OECD guidelines
Acute eye irritation test as per OECD guidelines
 
Acute eye irritation oecd
Acute eye irritation oecdAcute eye irritation oecd
Acute eye irritation oecd
 
Sub acute
Sub acuteSub acute
Sub acute
 
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptxTOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
 
Acute dermal irritation/corrosion: OECD 404
Acute dermal irritation/corrosion: OECD 404Acute dermal irritation/corrosion: OECD 404
Acute dermal irritation/corrosion: OECD 404
 
Oral toxicity
Oral toxicityOral toxicity
Oral toxicity
 
Toxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal IrritationToxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal Irritation
 
Regulatory guidelines for conducting toxicity studies by ich
Regulatory guidelines for conducting toxicity studies by ichRegulatory guidelines for conducting toxicity studies by ich
Regulatory guidelines for conducting toxicity studies by ich
 
Safety pharmacology studies
Safety pharmacology studies Safety pharmacology studies
Safety pharmacology studies
 
Regulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studiesRegulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studies
 
Acute toxicity study for inhalation
Acute toxicity study for inhalationAcute toxicity study for inhalation
Acute toxicity study for inhalation
 

Similar to AT425.pptx

Acute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guidelineAcute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guidelineDikuNath
 
Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Sagar Dalvi
 
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...Hemadharshini Senthill
 
General toxicology
General toxicologyGeneral toxicology
General toxicologyAsif Yahya
 
Introduction to toxicology
Introduction to toxicologyIntroduction to toxicology
Introduction to toxicologyManojKumar109262
 
oecdguidelinesfortoxicologystudies-180417193414 (11).pptx
oecdguidelinesfortoxicologystudies-180417193414 (11).pptxoecdguidelinesfortoxicologystudies-180417193414 (11).pptx
oecdguidelinesfortoxicologystudies-180417193414 (11).pptxAbhishekMahajan510050
 
Acute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsAcute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsSwaroopaNallabariki
 
Testing of Dermatotoxicity by OECD guidelines
Testing of Dermatotoxicity by OECD guidelinesTesting of Dermatotoxicity by OECD guidelines
Testing of Dermatotoxicity by OECD guidelinesGAUTAM KHUNE
 
INHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacyINHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacyAartiPal23
 
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptxAcute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptxDublinmatcher
 

Similar to AT425.pptx (20)

Acute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guidelineAcute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guideline
 
Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines
 
Oecd guidelines
Oecd guidelinesOecd guidelines
Oecd guidelines
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
 
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
 
OECD GUIDELINES.pptx
OECD GUIDELINES.pptxOECD GUIDELINES.pptx
OECD GUIDELINES.pptx
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
 
General toxicology
General toxicologyGeneral toxicology
General toxicology
 
Animal Toxicity Studies
Animal Toxicity StudiesAnimal Toxicity Studies
Animal Toxicity Studies
 
Toxicological screening
Toxicological screeningToxicological screening
Toxicological screening
 
Difference between toxicity studies
Difference between toxicity studiesDifference between toxicity studies
Difference between toxicity studies
 
Introduction to toxicology
Introduction to toxicologyIntroduction to toxicology
Introduction to toxicology
 
oecdguidelinesfortoxicologystudies-180417193414 (11).pptx
oecdguidelinesfortoxicologystudies-180417193414 (11).pptxoecdguidelinesfortoxicologystudies-180417193414 (11).pptx
oecdguidelinesfortoxicologystudies-180417193414 (11).pptx
 
Oecd guide line2
Oecd guide line2Oecd guide line2
Oecd guide line2
 
Oecd guide line2
Oecd guide line2Oecd guide line2
Oecd guide line2
 
Acute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsAcute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animals
 
Testing of Dermatotoxicity by OECD guidelines
Testing of Dermatotoxicity by OECD guidelinesTesting of Dermatotoxicity by OECD guidelines
Testing of Dermatotoxicity by OECD guidelines
 
INHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacyINHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacy
 
Tocixity studies
Tocixity studiesTocixity studies
Tocixity studies
 
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptxAcute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
 

More from SOUMYA PURANAM

More from SOUMYA PURANAM (6)

CYTOTOXIC Drugs .pptx
CYTOTOXIC Drugs .pptxCYTOTOXIC Drugs .pptx
CYTOTOXIC Drugs .pptx
 
Hormonal drugs.pptx
Hormonal drugs.pptxHormonal drugs.pptx
Hormonal drugs.pptx
 
drug barhemsys ..pptx
drug barhemsys ..pptxdrug barhemsys ..pptx
drug barhemsys ..pptx
 
cadd .pptx
cadd .pptxcadd .pptx
cadd .pptx
 
CRF case study.pptx
CRF case study.pptxCRF case study.pptx
CRF case study.pptx
 
UTI.pptx
UTI.pptxUTI.pptx
UTI.pptx
 

Recently uploaded

Natural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsNatural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsAArockiyaNisha
 
Botany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdfBotany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdfSumit Kumar yadav
 
GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)Areesha Ahmad
 
Biological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdfBiological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdfmuntazimhurra
 
Hubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsHubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsSérgio Sacani
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxAleenaTreesaSaji
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Sérgio Sacani
 
Spermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatidSpermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatidSarthak Sekhar Mondal
 
Formation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disksFormation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disksSérgio Sacani
 
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdfPests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdfPirithiRaju
 
VIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C PVIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C PPRINCE C P
 
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...ssifa0344
 
Disentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOSTDisentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOSTSérgio Sacani
 
Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)PraveenaKalaiselvan1
 
Botany 4th semester file By Sumit Kumar yadav.pdf
Botany 4th semester file By Sumit Kumar yadav.pdfBotany 4th semester file By Sumit Kumar yadav.pdf
Botany 4th semester file By Sumit Kumar yadav.pdfSumit Kumar yadav
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...jana861314
 
GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)Areesha Ahmad
 
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCESTERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCEPRINCE C P
 
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptxUnlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptxanandsmhk
 

Recently uploaded (20)

Natural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsNatural Polymer Based Nanomaterials
Natural Polymer Based Nanomaterials
 
Botany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdfBotany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdf
 
GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)
 
Biological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdfBiological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdf
 
Hubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsHubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroids
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptx
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
 
Spermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatidSpermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatid
 
Formation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disksFormation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disks
 
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdfPests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
 
VIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C PVIRUSES structure and classification ppt by Dr.Prince C P
VIRUSES structure and classification ppt by Dr.Prince C P
 
Engler and Prantl system of classification in plant taxonomy
Engler and Prantl system of classification in plant taxonomyEngler and Prantl system of classification in plant taxonomy
Engler and Prantl system of classification in plant taxonomy
 
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
 
Disentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOSTDisentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOST
 
Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)
 
Botany 4th semester file By Sumit Kumar yadav.pdf
Botany 4th semester file By Sumit Kumar yadav.pdfBotany 4th semester file By Sumit Kumar yadav.pdf
Botany 4th semester file By Sumit Kumar yadav.pdf
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
 
GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)
 
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCESTERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
 
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptxUnlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
 

AT425.pptx

  • 1. ACUTE TOXICOLOGY OECD GUIDELINES 425 Presented by PURANAM SOUMYA Y18PHD0417 III-PHARM.D
  • 2. TOXICOLOGY  Toxicology is the scientific study of adverse effects that occur in living organisms due to chemicals.  It involves observing and reporting symptoms, mechanisms, detection and treatments of toxic substances, in particular relation to the poisoning of humans.  Toxicity tests are mostly used to examine specific adverse events such as cancer, cardiotoxicity and skin/eye irritation
  • 3. ANIMAL TOXICITY TEST Acute toxicity Sub-acute (repeated doses) toxicity Sub-chronic toxicity Chronic toxicity Special toxicity 14 days 28 days 3 months 6 months to 2 yrs. e.g. Carcinogenicity
  • 4. ACUTE ORAL TOXICITY  Acute toxicity testing is carried out to determine the effect of a single dose on a particular animal species.  In acute toxicological testing, the investigational product is administered at different dose levels, and the effect is observed for 14 days.  All mortalities caused by the investigational product during the experimental period are recorded and morphological, biochemical, pathological, and histological changes in the dead animals are investigated.  Acute toxicity testing permits the 50% lethal dose (LD50) of the investigational product to be determined.  Acute toxicity studies provide information on: • The potential for acute toxicity in humans; • An estimate of safe acute doses for humans; • The potential target organs of toxicity; • Time course of drug-induced clinical observations; • The appropriate dosage for multiple-dose toxicity studies; and • Species differences in toxicity.
  • 5. OECD GUIDELINES FOR ACUTE ORAL TOXICITY Number TITLE Date of Adoption 420 Fixed dose procedure 17 December 2001 425 Up and down procedure 3 October 2008
  • 6. 425 : Acute oral toxicity – Up and Down Procedure (UDP) INTRODUCTION • The concept of the up-and-down testing approach was first described by Dixon and Mood. • In 1985, Bruce proposed to use an up-and-down procedure (UDP) for the determination of acute toxicity of chemicals . • A study comparing the results obtained with the UDP, the conventional LD50 test and the Fixed Dose Procedure (FDP,OECDTest Guideline 420) was published in 1995. • The test procedure described in this Guideline is of value in minimizing the number of animals required to estimate the acute oral toxicity of a chemical. In addition to the estimation of LD50 and confidence intervals, the test allows the observation of signs of toxicity.
  • 7. • The testing laboratory should consider all available information on the test substance prior to conducting the study. • It will include -Identity and chemical structure of the test substance; -Physical chemical properties; -Results of any other in vitro or in vivo toxicity tests on the substance; -Toxicological data on structurally related substances or similar mixtures; -Anticipated use(s) of the substance. • This information is useful to determine the relevance of the test for the protection of human health and the environment, and will help in the selection of an appropriate starting dose. • The method permits estimation of an LD50 with a confidence interval and the results allow a substance to be ranked and classified according to the Globally Harmonised System for the classification of chemicals which cause acute toxicity. INITIAL CONSIDERATIONS
  • 8. • Dose starting near 175mg/kg and using half log units (dose progression by factor 3.2) between doses will procedure best results. • Test substances, at doses that are known to cause marked pain and distress due to corrosive or severely irritant actions, need not be administered. • Moribund animals or animals obviously in pain or showing signs of severe and enduring distress shall be humanely killed, and are considered in the interpretation of the test results in the same way as animals that died on test. • The method would not be practical to use when considerably delayed death (five days or more) can be expected.
  • 9. PRINCIPLE OF LIMIT TEST • The LimitTest is a sequential test that uses a maximum of 5 animals.A test dose of 2000, or exceptionally 5000 mg/kg, may be used. • The selection of a sequential test plan increases the statistical power and also has been made to intentionally bias the procedure towards rejection of the limit test for compounds with LD50s near the limit dose. PRINCIPLE OF MAIN TEST • The main test consists of a single ordered dose progression in which animals are dosed, one at a time, at a minimum of 48-hour intervals. • The first animal receives a dose a step below the level of the best estimate of the LD50.
  • 10. • If the animal survives, the dose for the next animal is increased by [a factor of] • 3.2 times the original dose; if it dies, the dose for the next animal is decreased • by a similar dose progression. • Each animal should be observed carefully for up to 48 hours before making a decision on whether and how much to dose the next animal. • That decision is based on the 48-hour survival pattern of all the animals up to • that time. • The LD50 is calculated using the method of maximum likelihood
  • 11. DESCRIPTION OF METHOD Selection of animal species • The preferred rodent species is the rat ,normally female rats are used. • When toxicological or toxicokinetic properties of structurally related chemicals are studied, males are likely to be more sensitive. • Criteria for female rats -They should be nulliparous and non pregnant. - -Should be between 8 to 12 years old. -Weight ± 20% of initial mean weight
  • 12. Housing and feeding • Temperature - 22°C (± 3°C). • Humidity – 50 – 60% not exceeding 70% • Lighting should be artificial, the sequence being 12 hours light and 12 hours dark. • The animals are housed individually. • For feeding, conventional rodent laboratory diets may be used with an unlimited supply of drinking water.
  • 13. Preparation of animals • The animals are randomly selected, marked to permit individual identification, and kept in their cages for at least 5 days prior to dosing to allow for acclimatization to laboratory conditions. • Ensure that animals are available in the appropriate size and age range for the entire study. Preparation of doses • Test substances should be administered in a constant volume by varying the concentration of the dosing preparation. • In rodents, the volume should not normally exceed 1 ml/100g of body weight; however in the case of aqueous solutions, 2 ml/100g body weight can be considered. • For vehicles other than water, the toxicological characteristics of the vehicle should be known.
  • 14. PROCEDURE Administration of Doses • The test substance is administered in a single dose by gavage using a stomach tube or a suitable intubation cannula. • Animals should be fasted prior to dosing (e.g., with the rat, food but not water should be withheld overnight; with the mouse, food but not water should be withheld for 3-4 hours). • The animals should be weighed and the test substance administered and the dose is calculated according to the body weight. • After the substance has been administered, food may be withheld for a further 3-4 hours in rats or 1-2 hours in mice.
  • 15. Limit test and Main Test • The limit test is primarily used in situations where the experimenter has information indicating that the test material is likely to be nontoxic, i.e., having toxicity below regulatory limit doses. • There is little or no information about its toxicity, or in which the test material is expected to be toxic, the main test should be performed. • Information about the toxicity of the test material can be gained from knowledge about similar tested compounds or similar tested mixtures or products, taking into consideration the identity and percentage of components.
  • 16. Limit Test Limit Test at 2000 mg/kg • Dose one animal at the test dose. • If the animal dies, conduct the main test to determine the LD50. • If the animal survives, dose four additional animals sequentially so that a total of five animals are tested. If three animals die, the limit test is terminated and the main test is performed. • If an animal unexpectedly dies late in the study, and there are other survivors, it is appropriate to stop dosing and observe all animals to see if other animals will also die during a similar observation period. • The results are evaluated as follows (O=survival, X=death).
  • 17. • The LD50 is less than the test dose (2000 mg/kg) when three or more animals die. O XO XX O OX XX O XX OX O XX X If a third animal dies, conduct the main test. • Test five animals.The LD50 is greater than the test dose (2000 mg/kg) when three or more animals survive. O OO OO O OO XO O OO OX O OO XX O XOXO OXOOO/X O OXXO OOXOO/X O XXOO
  • 18. Limit Test at 5000 mg/kg • Dose one animal at the test dose. • If the animal dies, conduct the main test to determine the LD50. • If the animal survives, dose two additional animals. If both animals survive, the LD50 is greater than the limit dose and the test is terminated. • The LD50 is less than the test dose (5000 mg/kg) when three or more animals die. O XO XX O OX XX O XX OX OXXX0. The LD50 is greater than the test dose (5000 mg/kg) when three or more animals survive. OOO O XOXO O XOO O OXXO O OXO OXXOO
  • 19. Main Test • Single animals are dosed in sequence usually at 48 h intervals. • For selecting the starting dose, information on structurally related substances and results of any other toxicity tests on the test material, should be used to approximate the LD50 as well as the slope of the dose- response curve. • The dose progression factor should remain constant throughout testing. • When there is no information on the slope of the substance to be tested, a dose progression factor of 3.2 is used. • Using the default progression factor, doses would be selected from the sequence 1.75, 5.5, 17.5, 55, 175, 550, 2000 (or 1.75, 5.5, 17.5, 55, 175, 550, 1750, 5000 for specific regulatory needs).
  • 20. 1 animal 1.75mg/kg If the animal survives If the animal dies Next animal receives the higher dose 5.5mg/kg Classify GHS category 1 1 animal 5.5mg/kg If the animal survives If the animal dies Next animal receives the higher dose 17.5mg/kg Animal receives lower dose
  • 21.  The testing stops when one of the following stopping criteria first is met: (a)3 consecutive animals survive at the upper bound; (b)5 reversals occur in any 6 consecutive animals tested; (c)at least 4 animals have followed the first reversal and the specified likelihood-ratios exceed the critical value. • If an animal unexpectedly dies late in the study and there are other survivors at that dose or above, it is appropriate to stop dosing and observe all animals to see if other animals will also die during a similar observation period. • If subsequent survivors also die, and it appears that all dose levels exceed the LD50 it would be most appropriate to start the study again. • If subsequent animals survive at or above the dose of the animal that dies, it is not necessary to change the dose progression.
  • 22. OBSERVATIONS • Animals are observed individually at least once during the first 30 minutes after dosing, periodically during the first 24 hours for 14 days. • The times at which signs of toxicity appear and disappear are recorded. • Observations should include - changes in skin and fur - eyes and mucous membranes - respiratory, circulatory - autonomic and central nervous systems - somatomotor activity - behaviour pattern - tremors, convulsions - salivation - diarrhoea - lethargy - sleep and coma. • Animals found in a moribund condition and animals showing severe pain or enduring signs of severe distress should be humanely killed and time of death should be recorded.
  • 23. Bodyweight • Individual weights are recorded before the test drug administration and weekly thereafter. • At the end of the test surviving animals are weighed and then humanely killed. Pathology • All animals (including those which die during the test or are removed from the study for animal welfare reasons) should be subjected to gross necropsy. • Microscopic examination of organs showing evidence of gross pathology in animals surviving 24 or more hours after the initial dosing may also be considered.
  • 24. DATA AND REPORTING All data should be summarized in tabular form, showing for each test dose, -number of animals used -number of animals displaying signs of toxicity -number of animals found dead during the test or killed for humane reasons -time of death of individual animals -a description and the time course of toxic effects and reversibility -necropsy findings. CALCULATION OF LD 50 The LD50 is calculated using the maximum likelihood method Likelihood function is written as follows: L = L1 L2 ....Ln , where L is the likelihood of the experimental outcome, µ and σ, and n the total number of animals tested.
  • 25. Li = 1 - F(Zi) ,if the ith animal survived, or Li = F(Zi) if the ith animal died, where F = cumulative standard normal distribution, Zi = [log(di) - µ ] / σ di = dose given to the ith animal σ = standard deviation in log units of dose (usually 0.5) Estimated LD50 are available for these circumstances given below: a) If the upper bound dose ended testing, then the LD50 is reported to be above the upper bound. b) If all the dead animals have higher doses than all the live animals, then the LD50 is between the doses for the live and the dead animals which do not give exact value of LD50. c) If the live and dead animals have only one dose in common and all the other dead animals have higher doses and all the other live animals lower doses, or vice versa, then the LD50 equals their common dose.  Maximum likelihood calculation can be performed using either SAS (e.g., PROC NLIN) or BMDP (e.g., program AR) computer program packages.
  • 26. Computation of Confidence Interval Confidence intervals provides valuable information on the reliability and utility of the main test that was conducted • A wide confidence interval indicates that there is more uncertainty associated with the estimated LD50. The reliability of the estimated LD50 is low and the usefulness of the estimated LD50 may be marginal. • A narrow interval indicates that there is relatively little uncertainty associated with the estimated LD50. The reliability of the estimated LD50 is high and the usefulness of the estimated LD50 is good. • This means that if the main test were to be repeated, the new estimated LD50 should be close to the original estimated LD50 and both of these estimates should be close to the true LD50.
  • 27. TEST REPORT The test report must include the following information: • Test substance: –physical nature, purity and, where relevant, physical-chemical properties (including isomerization); –identification data, including CAS number. • Vehicle (if appropriate): –justification for choice of vehicle, if other than water. • Test animals: –species/strain used; –microbiological status of the animals, when known; –number, age and sex of animals (including, where appropriate, a rationale for use of males instead of females); –source, housing conditions, diet, etc.
  • 28. • Test conditions: – rationale for initial dose level selection, dose progression factor and for follow-up dose levels; – details of test substance formulation including details of the physical form of the material administered; – details of the administration of the test substance including dosing volumes and time of dosing; – details of food and water quality (including diet type/source, water source). Results: – body weight/body weight changes; – tabulation of response data and dose level for each animal (i.e., animals showing signs of toxicity including nature, severity, duration of effects, and mortality); – individual weights of animals at the day of dosing, in weekly intervals thereafter, and at the time of death or sacrifice ; – time course of onset of signs of toxicity and whether these were reversible for each animal; – necropsy findings and any histopathological findings for each animal, if available; − LD50 data; – statistical treatment of results.
  • 29. Comparison of guidelines Criteria 420 423 425 Dose 5 to 5000 mg/kg 5 to 5000 mg/kg 1st animal dose less than estimated LD50 outcome by factor 3.2 Grouping of animal Group of 5 animal of one sex Three animals per group One animal per group Estimation of end point 1 animal expected to die 2-3 animal expected to die 2-3 animal expected to die Sighting study Present Absent Absent